Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1‑RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaemia cells

Bashanfer,Salem Ali   Al‑Salem; Saleem,Mohamed; Heidenreich,Olaf; Moses,Emmanuel Jairaj; Yusoff,Narazah   Mohd

doi:10.3892/or.2018.6926

Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1‑RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaemia cells

Authors:
- Salem Ali Al‑Salem Bashanfer
- Mohamed Saleem
- Olaf Heidenreich
- Emmanuel Jairaj Moses
- Narazah Mohd Yusoff
View Affiliations

Affiliations: Hematology Department, College of Medicine and Health Sciences, University of Hodiedah, Hodiedah 3730, Yemen, Advanced Genomics Lab Sdn Bhd, Kota Damansara, Petaling Jaya, Selangor Darul Ehsan 47810, Malaysia, Northern Institute for Cancer Research, Medical School, Newcastle upon Tyne NE2 4HH, UK, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, Kepala Batas, Pulau Pinang 13200, Malaysia
Published online on: December 12, 2018 https://doi.org/10.3892/or.2018.6926
Pages: 2027-2040

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The t(8;21) translocation is one of the most frequent chromosome abnormalities associated with acute myeloid leukaemia (AML). This abberation deregulates numerous molecular pathways including the ERK signalling pathway among others. Therefore, the aim of the present study was to investigate the gene expression patterns following siRNA‑mediated suppression of RUNX1‑RUNX1T1 and MAPK1 in Kasumi‑1 and SKNO‑1 cells and to determine the differentially expressed genes in enriched biological pathways. BeadChip microarray and gene ontology analysis revealed that RUNX1‑RUNX1T1 and MAPK1 suppression reduced the proliferation rate of the t(8;21) cells with deregulated expression of several classical positive regulator genes that are otherwise known to enhance cell proliferation. RUNX1‑RUNX1T1 suppression exerted an anti‑apoptotic effect through the overexpression of BCL2, BIRC3 and CFLAR genes, while MAPK1 suppression induced apopotosis in t(8;21) cells by the apoptotic mitochondrial changes stimulated by the activity of upregulated TP53 and TNFSF10, and downregulated JUN gene. RUNX1‑RUNX1T1 suppression supported myeloid differentiation by the differential expression of CEBPA, CEBPE, ID2, JMJD6, IKZF1, CBFB, KIT and CDK6, while MAPK1 depletion inhibited the differentiation of t(8;21) cells by elevated expression of ADA and downregulation of JUN. RUNX1‑RUNX1T1 and MAPK1 depletion induced cell cycle arrest at the G0/G1 phase. Accumulation of cells in the G1 phase was largely the result of downregulated expression of TBRG4, CCNE2, FOXO4, CDK6, ING4, IL8, MAD2L1 and CCNG2 in the case of RUNX1‑RUNX1T1 depletion and increased expression of RASSF1, FBXO6, DADD45A and P53 in the case of MAPK1 depletion. Taken together, the current results demonstrate that MAPK1 promotes myeloid cell proliferation and differentiation simultaneously by cell cycle progression while suppresing apoptosis.

View Figures

View References

1	Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ and Burnett AK; National Cancer Research Institute Adult Leukaemia Working Group, : Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 116:354–365. 2010. View Article : Google Scholar : PubMed/NCBI
2	Nucifora G and Rowley JD: AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood. 86:1–14. 1995.PubMed/NCBI
3	Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N and Ohki M: The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12:2715–2721. 1993. View Article : Google Scholar : PubMed/NCBI
4	Chang KS, Fan YH, Stass SA, Estey EH, Wang G, Trujillo JM, Erickson P and Drabkin H: Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene. 8:983–988. 1993.PubMed/NCBI
5	Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G, Vornlocher HP and Nordheim A: AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood. 101:3157–3163. 2003. View Article : Google Scholar : PubMed/NCBI
6	Trombly DJ, Whitfield TW, Padmanabhan S, Gordon JA, Lian JB, van Wijnen AJ, Zaidi SK, Stein JL and Stein GS: Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. BMC Genomics. 16:3092015. View Article : Google Scholar : PubMed/NCBI
7	Hildebrand D, Tiefenbach J, Heinzel T, Grez M and Maurer AB: Multiple regions of ETO cooperate in transcriptional repression. J Biol Chem. 276:9889–9895. 2001. View Article : Google Scholar : PubMed/NCBI
8	Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K and Zhang DE: AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA. 98:10398–10403. 2001. View Article : Google Scholar : PubMed/NCBI
9	Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC and Alvarez S: Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia. 26:1329–1337. 2012. View Article : Google Scholar : PubMed/NCBI
10	Klampfer L, Zhang J, Zelenetz AO, Uchida H and Nimer SD: The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci USA. 93:14059–14064. 1996. View Article : Google Scholar : PubMed/NCBI
11	Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, et al: The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med. 8:743–750. 2002. View Article : Google Scholar : PubMed/NCBI
12	Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W and Behre G: The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood. 101:270–277. 2003. View Article : Google Scholar : PubMed/NCBI
13	Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE and Tenen DG: AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 7:444–451. 2001. View Article : Google Scholar : PubMed/NCBI
14	Rio-Machín A, Menezes J, Maiques-Diaz A, Agirre X, Ferreira BI, Acquadro F, Rodriguez-Perales S, Juaristi KA, Alvarez S and Cigudosa JC: Abrogation of RUNX1 gene expression in de novo myelodysplastic syndrome with t(4;21)(q21;q22). Haematologica. 97:534–537. 2012. View Article : Google Scholar : PubMed/NCBI
15	McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773. 1263–1284. 2007.
16	Morgan MA, Dolp O and Reuter CW: Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 97:1823–1834. 2001. View Article : Google Scholar : PubMed/NCBI
17	Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M and Saito H: Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia. 11:479–484. 1997. View Article : Google Scholar : PubMed/NCBI
18	Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E and Andreeff M: Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 108:851–859. 2001. View Article : Google Scholar : PubMed/NCBI
19	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
20	Zaidi SK, Dowdy CR, van Wijnen AJ, Lian JB, Raza A, Stein JL, Croce CM and Stein GS: Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network. Cancer Res. 69:8249–8255. 2009. View Article : Google Scholar : PubMed/NCBI
21	Spirin PV, Lebedev TD, Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA, Dmitriev SE, Buzdin AA, Borisov NM, Aliper AM, et al: Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. Leukemia. 28:2222–2228. 2014. View Article : Google Scholar : PubMed/NCBI
22	Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4:P32003. View Article : Google Scholar : PubMed/NCBI
23	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
24	Huang da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
25	Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P and Kuo MC: Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 18:466–475. 2004. View Article : Google Scholar : PubMed/NCBI
26	Bacher U, Haferlach T, Kern W, Haferlach C and Schnittger S: A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 92:744–752. 2007. View Article : Google Scholar : PubMed/NCBI
27	Martinez N, Drescher B, Riehle H, Cullmann C, Vornlocher HP, Ganser A, Heil G, Nordheim A, Krauter J and Heidenreich O: The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer. 4:442004. View Article : Google Scholar : PubMed/NCBI
28	Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, Iwasaki H, Niiro H, Takenaka K, Nagafuji K, Harada M, et al: Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol. 180:7358–7367. 2008. View Article : Google Scholar : PubMed/NCBI
29	Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S and Griffin JD: Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 78:2962–2968. 1991.PubMed/NCBI
30	Woźniak J and Kopeć-Szlezak J: c-Kit receptor (CD117) expression on myeloblasts and white blood cell counts in acute myeloid leukemia. Cytometry Part B Clin Cytometry. 58:9–16. 2004. View Article : Google Scholar
31	Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, et al: Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 377:454–464. 2017. View Article : Google Scholar : PubMed/NCBI
32	Dong Chen, Waters SB, Holt KH and Pessin JE: SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J Biol Chem. 271:6328–6332. 1996. View Article : Google Scholar : PubMed/NCBI
33	Pedram A, Razandi M and Levin ER: Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem. 273:26722–26728. 1998. View Article : Google Scholar : PubMed/NCBI
34	Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, et al: Expression of Bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid. Leukemia. 13:1881–1892. 1999. View Article : Google Scholar : PubMed/NCBI
35	Wang X: The expanding role of mitochondria in apoptosis. Genes Dev. 15:2922–2933. 2001.PubMed/NCBI
36	Salvesen GS and Duckett CS: IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol. 3:401–410. 2002. View Article : Google Scholar : PubMed/NCBI
37	Westwick JK, Cox AD, Der CJ, Cobb MH, Hibi M, Karin M and Brenner DA: Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases. Proc Natl Acad Sci USA. 91:6030–6034. 1994. View Article : Google Scholar : PubMed/NCBI
38	Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, Shigematsu H, Levantini E, Huettner CS, Lekstrom-Himes JA, et al: Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 21:853–863. 2004. View Article : Google Scholar : PubMed/NCBI
39	Yamanaka R, Barlow C, Lekstrom-Himes J, Castilla LH, Liu PP, Eckhaus M, Decker T, Wynshaw-Boris A and Xanthopoulos KG: Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci USA. 94:13187–13192. 1997. View Article : Google Scholar : PubMed/NCBI
40	Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ and Timchenko NA: C/EBPα arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell. 8:817–828. 2001. View Article : Google Scholar : PubMed/NCBI
41	Ishiguro A, Spirin KS, Shiohara M, Tobler A, Gombart AF, Israel MA, Norton JD and Koeffler HP: Id2 expression increases with differentiation of human myeloid cells. Blood. 87:5225–5231. 1996.PubMed/NCBI
42	Fujimoto T, Anderson K, Jacobsen SE, Nishikawa Si and Nerlov C: Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. EMBO J. 26:2361–2370. 2007. View Article : Google Scholar : PubMed/NCBI
43	Rangatia J, Vangala RK, Treiber N, Zhang P, Radomska H, Tenen DG, Hiddemann W and Behre G: Downregulation of c-Jun expression by transcription factor C/EBPα is critical for granulocytic lineage commitment. Mol Cell Biol. 22:8681–8694. 2002. View Article : Google Scholar : PubMed/NCBI
44	Shivakumar L, Minna J, Sakamaki T, Pestell R and White MA: The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol. 22:4309–4318. 2002. View Article : Google Scholar : PubMed/NCBI
45	Kearsey JM, Coates PJ, Prescott AR, Warbrick E and Hall PA: Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1. Oncogene. 11:1675–1683. 1995.PubMed/NCBI
46	Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA and Musunuru K: Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell. 12:393–394. 2013. View Article : Google Scholar : PubMed/NCBI
47	Shafie NH, Saleem M, Moses EJ, Razak SR and Yusoff NM: The CRISPR-Cas9 system: A new dawn in gene editing. J Bioanalys Biomed. 6:45–48. 2014.
48	Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z and Joung JK: High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 529:490–495. 2016. View Article : Google Scholar : PubMed/NCBI